In vivo and in vitro evaluation of four different aqueous polymeric dispersions for producing an enteric coated tablet

1995 ◽  
Vol 115 (1) ◽  
pp. 29-34 ◽  
Author(s):  
Marc S. Gordon ◽  
Anthony Fratis ◽  
Ronald Goldblum ◽  
Donald Jung ◽  
Kenneth E. Schwartz ◽  
...  
Keyword(s):  
In Vitro Evaluation ◽  
Enteric Coated Tablet ◽  
Coated Tablet ◽  
Enteric Coated ◽  
Polymeric Dispersions

scholarly journals Formulation and In-Vitro Evaluation of Enteric Coated Tablet Incorporating Rabeprazole

2020 ◽  
Vol 10 (2-s) ◽  
pp. 50-57
Author(s):  
Gautam D. Mehetre ◽  
Rameshwar S. Cheke ◽  
Vinayak N. Shrikhande
Keyword(s):  
Drug Release ◽  
Acid Resistance ◽  
Tablet Formulation ◽  
In Vitro Dissolution ◽  
Content Uniformity ◽  
In Vitro Evaluation ◽  
Enteric Coated Tablet ◽  
Coated Tablet ◽  
Enteric Coated

The objective of the work is to try and assess the applicability and manufacturing possibilities to optimize an enteric coated tablet formulation containing Rabeprazole sodium as the drug aiming at the anti-acidity activity with desired drug release properties. Enteric coated tablet was chosen as dosage form being a cost-effective technology for pharmaceutical industry requiring fewer procedures. Before the implementation of the pharmaceutical technological aims, analysis of critical factors influencing the manufacture was carried out. Reproducible manufacturing processes are required to achieve suitability and tablets uniformity to achieve the uniform properties of tablets, which could influence experimental parameters. Rabeprazole in core content of tablet is blended with HPMC (different grades), xanthan gum, PVPK30, mannitol, crosspovidone, Sodium starch glycolate, Colloidal silicon dioxide to formulate the product. Prepared formulation was tested for weight and content uniformity, physical characteristics, in vitro dissolution behaviour, acid resistance and accelerated stability studies. All studies performed resulted and revealed for assurance of such enteric coated tablet formulation for drug Rabeprazole with optimum characteristics, concluding it as a promising approach to enhance drug release characteristics. Keywords: Rabeprazole, HPMC, enteric coated tablets, In Vitro evaluation.

scholarly journals Evaluation of Enteric Coated Tablet Sensitive to Pancreatic Lipase. I, In Vitro Disintegration Test.

1992 ◽  
Vol 40 (7) ◽  
pp. 1902-1905
Author(s):  
Hironori YOSHITOMI ◽  
Yoshihiro SHIZUKU ◽  
Yasuko MASUDA ◽  
Rie ITAKURA ◽  
Motoko KANKE ◽  
...  
Keyword(s):  
Pancreatic Lipase ◽  
Enteric Coated Tablet ◽  
Coated Tablet ◽  
Enteric Coated ◽  
In Vitro Disintegration

scholarly journals Evaluation of Enteric Coated Tablet Sensitive to Pancreatic Lipase. II. In vivo Evaluation.

1993 ◽  
Vol 16 (12) ◽  
pp. 1260-1263 ◽  
Author(s):  
Hironori YOSHITOMI ◽  
Yoshihiro SHIZUKU ◽  
Yasuko MASUDA ◽  
Rie ITAKURA ◽  
Satoko OKAMOTO ◽  
...  
Keyword(s):  
Pancreatic Lipase ◽  
In Vivo Evaluation ◽  
Enteric Coated Tablet ◽  
Coated Tablet ◽  
Enteric Coated

scholarly journals Formulation and evaluation of enteric coated tablet of Ilaprazole

2013 ◽  
Vol 2 (7) ◽  
pp. 126-130 ◽  
Author(s):  
Surya Bhan Singh Rathore ◽  
Anshu Sharma ◽  
Ayush Garg ◽  
Dharmendra Singh Sisodiya
Keyword(s):  
In Vitro Release ◽  
Pharmaceutical Journal ◽  
Release Profile ◽  
Enteric Coating ◽  
Enteric Coated Tablet ◽  
Triethyl Citrate ◽  
Coated Tablet ◽  
Enteric Coated ◽  
Vitro Release

The present study was an attempt to formulate and evaluate enteric coated tablets for Ilaprazole to reduce the gastrointestinal tract side effects. Four formulations of core tablets were prepared and one who shows rapid disintegration (near around three minutes) was selected for enteric coating. Ilaprazole which have an irritant effect on the stomach can be coated with a substance that will only dissolve in the small intestine. Enteric coat was optimized using two different polymers such as HPMCP 50 and Eudragit L 100 in different concentrations. The prepared tablets were evaluated in terms of their pre-compression parameters, physical characteristics and in-vitro release study. 2.5% seal coating on core tablets was optimized and 9% enteric coating on seal coated tablets was performed using HPMC P 50 (60%), triethyl citrate (10%) and IPA:DCM (60:40) which gives the highest dissolution release profile and f2 value.DOI: http://dx.doi.org/10.3329/icpj.v2i7.15156 International Current Pharmaceutical Journal, June 2013, 2(7): 126-130

scholarly journals In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Michele Dei Cas ◽  
Jessica Rizzo ◽  
Mariangela Scavone ◽  
Eti Femia ◽  
Gian Marco Podda ◽  
...  
Keyword(s):  
Oral Administration ◽  
Whole Blood ◽  
Serum Levels ◽  
Reversed Phase ◽  
Weekly Treatment ◽  
Low Dose Aspirin ◽  
Liquid Chromatography Tandem Mass ◽  
Enteric Coated

AbstractLow-dose aspirin (ASA) is used to prevent cardiovascular events. The most commonly used formulation is enteric-coated ASA (EC-ASA) that may be absorbed more slowly and less efficiently in some patients. To uncover these “non-responders” patients, the availability of proper analytical methods is pivotal in order to study the pharmacodynamics, the pharmacokinetics and the metabolic fate of ASA. We validated a high-throughput, isocratic reversed-phase, negative MRM, LC–MS/MS method useful for measuring circulating ASA and salicylic acid (SA) in blood and plasma. ASA-d4 and SA-d4 were used as internal standards. The method was applied to evaluate: (a) the "in vitro" ASA degradation by esterases in whole blood and plasma, as a function of time and concentration; (b) the "in vivo" kinetics of ASA and SA after 7 days of oral administration of EC-ASA or plain-ASA (100 mg) in healthy volunteers (three men and three women, 37–63 years). Parameters of esterases activity were Vmax 6.5 ± 1.9 and Km 147.5 ± 64.4 in plasma, and Vmax 108.1 ± 20.8 and Km 803.2 ± 170.7 in whole blood. After oral administration of the two formulations, tmax varied between 3 and 6 h for EC-ASA and between 0.5 and 1.0 h for plain-ASA. Higher between-subjects variability was seen after EC-ASA, and one subject had a delayed absorption over eight hours. Plasma AUC was 725.5 (89.8–1222) for EC-ASA, and 823.1(624–1196) ng h/mL (median, 25–75% CI) for plain ASA. After the weekly treatment, serum levels of TxB2 were very low (< 10 ng/mL at 24 h from the drug intake) in all the studied subjects, regardless of the formulation or the tmax. This method proved to be suitable for studies on aspirin responsiveness.

Sign in / Sign up

Export Citation Format

Share Document